View in EDS

A Phase III, multicenter, randomized, double-blind, active comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of V114 compared with PCV13 in healthy infants (PNEU-PED-EU-1).

Saved in:
Bibliographic Details
Title: A Phase III, multicenter, randomized, double-blind, active comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of V114 compared with PCV13 in healthy infants (PNEU-PED-EU-1).
Authors: Martinon-Torres, Federico1,2,3 (AUTHOR), Wysocki, Jacek4 (AUTHOR), Szenborn, Leszek5 (AUTHOR), Carmona-Martinez, Alfonso6 (AUTHOR), Poder, Airi7 (AUTHOR), Dagan, Ron8 (AUTHOR), Richmond, Peter9 (AUTHOR), Gilbert, Christopher10 (AUTHOR), Trudel, Marie-Chantale11 (AUTHOR), Flores, Sheryl10 (AUTHOR), Lupinacci, Robert10 (AUTHOR), McFetridge, Richard10 (AUTHOR), Wiedmann, Richard T.10 (AUTHOR), Chen, Qiuxu10 (AUTHOR), Gerrits, Han12 (AUTHOR), Banniettis, Natalie1,10 (AUTHOR) natalie.banniettis@merck.com, Musey, Luwy10 (AUTHOR), Bickham, Kara10 (AUTHOR), Kaminski, Janusz13 (AUTHOR)
Source: Vaccine. May2023, Vol. 41 Issue 21, p3387-3398. 12p.
Database: Environment Complete
Description
ISSN:0264410X
DOI:10.1016/j.vaccine.2023.04.036